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ABSTRACT
Acquired resistance to penicillin-b-lactamase inhibitor combinations in Escherichia coli is due to: (i)
penicillinase hyperproduction due to the presence of the blaTEM-1 gene in small multicopy plasmids or
strong promoters; (ii) overproduction of constitutive AmpC cephalosporinase; and (iii) OXA-type and
inhibitor-resistant TEM (IRT) b-lactamases. IRT enzymes emerge via mutational events from TEM-1 or
TEM-2 b-lactamases that affect substrate afﬁnity for b-lactamase inhibitors. They are mainly isolated in
urinary infections from community patients. Prevalence is variable, depending on geographical area,
detection methods and potential selection pressure. These enzymes may evolve into complex mutants
(CMT enzymes), which also confer resistance to extended-spectrum cephalosporins. CTX-M enzymes
with the IRT phenotype have not been detected to date. New studies of IRT enzymes, including
population structure, association with virulence traits and plasmid dispersion, are needed.
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INTRODUCTION
Production of b-lactamases is the most important
mechanism of resistance against b-lactam antibiot-
ics. These enzymes constitute a family of proteins
that degrade or modify the b-lactam drugs before
they can reach the penicillin-binding protein target
sites. They covalently bind to the carbonyl moiety
of the b-lactam ring and hydrolyse its amide bond
[1,2]. Although the ﬁrst recognised b-lactamase
was identiﬁed in 1940 in Escherichia coli (formerly
Bacillus coli), the importance of this resistance
mechanism was not perceived until 1944, when
penicillinase production in Staphylococcus aureus
was associated with clinical failure. At that time,
fewer than 10% of S. aureus isolates were able to
produce this enzyme, but by the 1950s this propor-
tion had reached as high as 80%. The problem of
b-lactamase production inGram-negatives became
apparent in the 1960swith theﬁrst descriptionof an
E. coli isolate resistant to aminopenicillins due to
the production of TEM-1 b-lactamase. The corre-
sponding bla gene encoding this enzyme was
carried in a transposable element (Tn3) by plas-
mids of different incompatibility groups, which
subsequently were responsible for the rapid
increase in prevalence of TEM-1-producing iso-
lates. Both staphylococcal penicillinase and TEM-1
enzymes belong to Ambler class A of the serine
b-lactamases. Other serine b-lactamases belong
to classes C and D, whereas zinc metallo-b-lacta-
mases belong to class B.
During the 1970s and 1980s, there were differ-
ent approaches to circumvent b-lactamase-medi-
ated resistance, including the development of
b-lactam compounds resistant to hydrolysis, and
of b-lactamase inhibitors. The latter strategy gave
rise to a series of different compounds such as
boronates, phosphonates, and b-lactam-related
compounds that act as suicide inhibitors. This
allowed the introduction of commercial class A
b-lactamase inhibitors with high afﬁnity for
b-lactamases, acting as ‘suicide substrates’ of
these enzymes [3]. This group includes clavula-
nate, sulbactam and tazobactam [2]. All of these
are effective in inhibiting broad-spectrum b-lac-
tamases such as TEM-1, TEM-2 and SHV-1 and
their extended-spectrum b-lactamase (ESBL) vari-
ants, along with the more recently described CTX-
M enzymes [4,5]. Nevertheless, bacteria have
developed b-lactamase variants that are able to
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resist the action of suicide inhibitors. Within this
group are the so-called inhibitor-resistant
TEM (IRT) b-lactamases, which emerged in the
1990s, being mainly found in urine isolates [6–9].
Although these enzymes have not achieved the
prominence of ESBLs, they have been associated
with clinical failure with the use of b-lactam–-
b-lactamase inhibitor combinations [10–12].
MECHANISMS AFFECTING
b -LACTAM–b -LACTAMASE
INHIBITOR COMBINATIONS IN
GRAM-NEGATIVE BACTERIA
Resistance to inhibitors of class A b-lactamases
and their commercial combinations with b-lactam
antibiotics (amoxycillin–clavulanate, ampicillin–
sulbactam, ticarcillin–clavulanate, cefoperazone–
sulbactam and piperacillin–tazobactam) may
emerge as a consequence of different mecha-
nisms. In some cases, there are intrinsic resistance
mechanisms due to natural production of differ-
ent chromosomal b-lactamases that are not inhib-
ited, or are weakly inhibited, by these b-lactamase
inhibitors, such as the AmpC b-lactamases in
Enterobacter, Citrobacter, Serratia, Morganella and
Pseudomonas aeruginosa, or metallo-b-lactamases
such as L1 in Stenotrophomonas maltophilia [2].
In other cases, hyperproduction of constitutive
chromosomal b-lactamases can also reduce the
activity of b-lactam–b-lactamase inhibitor combi-
nations. This is the case for AmpC hyperproduc-
tion in E. coli and SHV-1 hyperproduction in
Klebsiella pneumoniae isolates [13–16].
The hyperproduction of TEM-1 b-lactamase
due to the presence of highly efﬁcient promoters
or to the presence of the corresponding bla gene in
different copies may result in the loss of
susceptibility to amoxycillin–clavulanate and
other b-lactam–b-lactamase inhibitor combina-
tions. In the ﬁrst case, strong promoters have
been shown with TEM-1 and TEM-2 enzymes and
their corresponding ESBL variants, as well as with
SHV ESBLs [17–21]. In the second case, multiple
blaTEM-1 copies may arise as a consequence of their
presence in the same plasmid or of being encoded
by small plasmids, with at least ten copies per
bacterial chromosome [18,22]. Hyperproduction
of SHV-1 or SHV ESBL variants has also been
described, but with lower frequency than that of
TEM-1 [20,23]. Nevertheless, the simultaneous
presence of an ESBL and a broad-spectrum
b-lactamase is not an infrequent event, thus
increasing the net quantity of b-lactamase that
needs to be inhibited by the b-lactamase inhibitor.
This situation slightly reduces the susceptibility to
b-lactam–b-lactamase inhibitor combinations [15].
In E. coli, resistance to inhibitor combinations
may emerge if susceptible enzymes occur in
combination with permeability deﬁciencies
involving OmpF and ⁄ or OmpC porins [24]. The
lack of one or two of these porins does not
signiﬁcantly affect the susceptibility to either
b-lactam agent, alone or combined; however, it
becomes relevant when both are associated in the
presence of a b-lactamase. Moreover, the
concomitant presence of different b-lactamases
also affects b-lactam–b-lactamase inhibitor
combinations. This is particularly important when
OXA-type b-lactamases are expressed, as these
enzymes are only weakly inhibited by clavulanate
and other inhibitors of class A b-lactamases [25].
The presence of these enzymes consequently
reduces the activity of inhibitor combinations
[26,27].
IRT ENZYMES
Deﬁnition
IRT enzymes represent an adaptive resistance
mechanism speciﬁcally developed by bacteria to
overcome the activity of b-lactamase inhibitors [7].
IRT enzymes (Bush–Jacoby–Medeiros group
2br) comprise a group of plasmid-encoded vari-
ants of TEM-1 and TEM-2 with decreased afﬁn-
ities for amino-, carboxy- and ureido-penicillins
and altered interactions with irreversible suicide
inhibitors such as clavulanate, sulbactam and
tazobactam. IRT-producing isolates remain sus-
ceptible to narrow- and extended-spectrum ceph-
alosporins, cephamycins, carbapenems and, in
most cases, piperacillin–tazobactam. However,
they are resistant to ampicillin–sulbactam and
intermediately resistant or resistant to amoxycil-
lin–clavulanate [28] (Table 1). Amino-acid
replacements at various positions in the original
TEM enzymes are responsible for the resistance
proﬁles of IRT producers (Table 2).
Initially found in E. coli [29], IRTs have also
been reported in Klebsiella spp., Enterobacter
cloacae, Proteus mirabilis, Citrobacter freundii and
Shigella sonnei [28,30]. They were originally
named TRC (TEM enzymes resistant to
54 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 53–62
clavulanic acid) [29], and later TRI (TEM resis-
tant to b-lactamase inhibitors) [31], and were
ﬁnally named IRT [10]. The presence of IRTs in
P. aeruginosa or other non-fermenters has not
been reported. The occurrence of an undetectable
IRT phenotype in these genera, which cannot be
completely ruled out, could be attributable to the
presence of a superimposed resistance mecha-
nism masking the IRT enzyme.
Structure–function relationships
The inhibition mechanisms exerted by clavula-
nate, sulbactam and tazobactam are quite similar
Table 1. b-Lactam phenotypes due
to the expression of different types
of b-lactamase in Escherichia coli
b-Lactamase AMX AMC TIC T ⁄C PIP P ⁄T 1st-CEP FOX 3rd-CEP
TEM-1 R S R S I ⁄R S S ⁄ I ⁄R S S
TEM-1 higha R I ⁄R R I ⁄R R S ⁄ I ⁄R I ⁄R S S
OXA-1 R I ⁄R R I ⁄R R I ⁄R R S Sb
IRT type R I ⁄R I ⁄R I ⁄R S ⁄ I ⁄R S ⁄ I ⁄R S S S
CMT type R R R I ⁄R R I ⁄R I ⁄R S I ⁄R
ESBL type R S ⁄ I R S I ⁄R S ⁄ I R S Rc
AmpC high R R I ⁄R I ⁄R I ⁄R I ⁄R R I ⁄R S ⁄ I ⁄R
AMX, amoxycillin; AMC, amoxycillin–clavulanate; TIC, ticarcillin; T ⁄C,
ticarcillin–clavulanate; PIP, piperacillin; P ⁄T, piperacillin–tazobactam; 1st-CEP,
ﬁrst-generation cephalosporins; FOX, cefoxitin; 3rd-CEP, third-generation
cephalosporins; ESBL, extended-spectrum b-lactamase; S, susceptible; R,
resistant; I, intermediate.
aHyperproduction of the corresponding b-lactamase.
bFourth-generation cephalosporins might be affected.
cIn some ESBL producing isolates, third-generation cephalosporins may be less
affected.
Table 2. Amino-acid substitutions
in inhibitor-resistant b-lactamases
derived from TEM-1 and TEM-2
based on http://www.lahey.org/
studies/temtable.asp
b-Lactamases
Amino-acid at position
21 39 69 127 130 165 182 244 261 265 275 276 pI
TEM-1 Leu Gln Met Ile Ser Trp Met Arg Val Thr Arg Asn 5.4
TEM-30 (IRT-2) Ser 5.2
TEM-31 (IRT-1) Cys 5.2
TEM-32 (IRT-3) Ile Thr 5.4
TEM-33 (IRT-5) Leu 5.4
TEM-34 (IRT-6) Val 5.4
TEM-35 (IRT-4) Leu Asp 5.2
TEM-36 (IRT-7) Val Asp 5.2
TEM-38 (IRT-9) Val Leu 5.2
TEM-39 (IRT-10) Leu Arg Asp 5.4
TEM-40 (IRT-11) Ile 5.4
TEM-45 (IRT-14) Leu Gln 5.2
TEM-51 (IRT-15) His 5.2
TEM-58 Ser Ile NA
TEM-73 (IRT-18) Phe Cys Met 5.2
TEM-74 (IRT-19) Phe Ser Met 5.2
TEM-76 (IRT-20) Gly NA
TEM-77 (IRT-21) Leu Ser NA
TEM-78 (IRT-22) Val Arg Asp NA
TEM-80 (IRT-24) Leu Val Asp 5.2
TEM-103 (IRT-28) Leu 5.2
TEM-2 Lys 5.6
TEM-44 (IRT-13) Lys Ser 5.4
TEM-59 (IRT-17) Lys Gly 5.6
TEM-65 (IRT-16) Lys Cys 5.4
NA, not available.
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and involve a secondary covalent cross-linking
reaction (between Ambler positions Ser70 and
Ser130 of TEM b-lactamase) after the initial
nucleophilic attack by the enzyme on the b-lactam
ring [32]. Analysis of X-ray crystallographic
structure and site-directed mutagenesis have been
used to assess the effect of speciﬁc amino-acid
substitutions in IRT enzymes and the correspond-
ing diminution or even abolition of b-lactam
inhibitor activity. The basis of resistance to inhi-
bition consists of a set of subtle but crucial
structural modiﬁcations due to amino-acid
changes (conﬁrmed by atomic resolution) that
lead to the perturbation of the local environment
of the cross-linking point (Ser130 in the parental
enzyme), but have less effect on the hydrolytic
mechanism. These amino-acid replacements,
either alone or in combination, are usually found
at positions Met69, Arg244, Asn276 and Leu275 of
TEM-1 and -2 [6,9]. Although infrequently found
among clinical isolates, some IRT variants (TEM-
59, -76 and -89) have a simple amino-acid change,
speciﬁcally, substitution of the highly conserved
Ser130 itself (in all cases by a glycine residue),
thereby preventing the mechanism-based inhibi-
tion [32,33]. Substitutions of other residues, such
as Trp165, Met182 and Val261, have also been
reported, as well as silent mutations that do not
affect the amino-acid sequence from progenitor
blaTEM genes [9,10,34] (Table 2). The traceability of
blaIRT genes enables them to be grouped in three
principal linkage groups: TEM-1A-like, TEM-1B-
like and TEM-2-like. Further analysis of promoter
and coding region sequences of blaIRT genes
demonstrated that a given mutation could be
associated with two different gene sequence
frameworks, and two different mutations could
reside in one and the same framework. A con-
vergent evolution model is therefore accepted for
IRT enzymes, as mutations have occurred inde-
pendently in different gene frameworks [35].
Consumption of b-lactam–b-lactamase inhibitor
formulations is considered to be a risk-factor for
the selection of IRT enzymes. It has been con-
ﬁrmed that avoidance of strong exposure to these
associations is clinically relevant in order to
circumvent the risk of treatment failures [12].
IRT kinetic parameters and inhibitor proﬁles
Kcat, Km and catalytic efﬁciency (Kcat ⁄Km) data
reveal that most IRT enzymes have lower catalytic
efﬁciency for all substrates than does TEM-1, due
to decreased Kcat and high Km values [9]. IC50s of
inhibitors are higher than those of TEM-1, and
sulbactam is the least effective inhibitor against
these enzymes (highest IC50 and Ki values) [7,36].
The piperacillin–tazobactam combination retains
inhibitory activity against most isolates with IRT
enzymes, probably owing to the increased activity
of piperacillin as compared with that of amoxy-
cillin and the strong inhibitory activity of tazo-
bactam, except when mutations at position 69 are
present [37]. Nevertheless, it is of note that this
combination appears, at least in vitro, to be bac-
teriostatic, with bacterial regrowth consistently
detected at 24 h [9].
Geographical distribution and epidemiology of
IRT-harbouring isolates
Despite the overuse of b-lactam–b-lactamase
inhibitor formulations in most countries, IRTs
have been more frequently found in Europe than
in the USA, where they have been rarely reported
[38]. Their presence has also been detected in
Malaysian E. coli isolates [39]. However, there is a
clear dearth of information about IRT geograph-
ical distribution, probably due to insufﬁcient
identiﬁcation using standard laboratory suscepti-
bility tests.
IRT b-lactamases occur among both commu-
nity- and hospital-acquired isolates. In general,
the pattern of the appearance of IRTs in both
settings cannot be ascribed to an epidemic phe-
nomenon. Conversely, the independent emer-
gence of these variants in non-related strains
may be explained by the strong selective pressure
exerted by overuse of b-lactam–b-lactamase inhib-
itor combinations [34].
Reports on the prevalence of clinical E. coli
isolates with IRT enzymes among those with
reduced susceptibility or resistance to
amoxycillin–clavulanate are scarce. To date, two
main studies have been published in Spain,
reporting percentages of 5.4% [40] and 9.5%
[41]. In a recent follow-up in our hospital, the
prevalence of E. coli isolates resistant to clavula-
nate was lower than 5%, with fewer than 3% of
isolates displaying an IRT phenotype (unpub-
lished data). In France, the reported frequency in
1993 of resistance to amoxycillin–clavulanate
(MIC >16 ⁄ 2 mg ⁄L) was 25.0% in hospital isolates
and 10.0% in community urinary tract infection
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isolates. Respectively, 27.5% and 45.0% of hospi-
tal and community isolates resistant to amoxycil-
lin–clavulanate exhibited the presence of an IRT
pattern [11]. More recently published data [42]
indicate a frequency of 41.2% of IRTs among
amoxycillin–clavulanate-resistant E. coli isolates
recovered from hospitalised patients (mainly iso-
lated from respiratory tract samples), while in the
UK in 1995, there was a 4% incidence of E. coli
isolates resistant to amoxycillin–clavulanate [19].
It is noteworthy that the ﬁrst IRTs in the USA (two
hospital E. coli isolates) were not reported until
2004 [38], despite the wide use of b-lactam–
b-lactamase inhibitor combinations in that coun-
try. In the same year, the appearance of the IRT-2
enzyme in three strains (same ribotype) of the
endemic KPC-2-harbouring K. pneumoniae recov-
ered at different hospitals in New York was
reported [43]. Contributing to these data, an
incidence of 16.1% of IRTs in clinical E. coli
isolates from hospitalised patients in Malaysia
has been observed [39].
At present, only one outbreak involving an IRT
enzyme has been described. This outbreak was
the result of the dissemination of clonally related
IRT-2-producing K. pneumoniae isolates recovered
in a geriatric facility in France. The blaIRT-2 gene
was harboured in a non-conjugative plasmid [44].
Detection of IRTs
Standard in-vitro susceptibility tests are not suf-
ﬁciently reliable for identiﬁcation of IRTs, and
discrepancies have been observed when compar-
ing disk-diffusion and MIC results, particularly in
those isolates with intermediate resistance values.
Differences between breakpoint values of inter-
national guidelines and inhibitor concentration
make comparisons even more complicated, par-
ticularly comparison of results reported from
various surveillance studies [38]. Disk inhibition
diameters of cefepime, ceftazidime and mecilli-
nam have been suggested to improve IRT detec-
tion [45]. Additional determinations of pI and
kinetic parameters are useful tools, although ﬁnal
conﬁrmation by molecular techniques, compris-
ing PCR of the coding gene and subsequent
sequencing of the product, are crucial for deﬁnite
identiﬁcation.
Another conﬂicting aspect of susceptibility
testing relates to the discrepant values obtained
when using a ﬁxed b-lactam ⁄b-lactamase inhibi-
tor ratio (e.g., 2:1 amoxcyillin to clavulanate) as
opposed to a ﬁxed concentration of inhibitor
(2 mg ⁄L or 4 mg ⁄L for clavulanate) [28,41,46]. It is
generally accepted that these different approaches
do not produce comparable results. In general, the
use of a ﬁxed concentration of 2 mg ⁄L of clavul-
anate (still not standardised worldwide) is pref-
erable for detection of the presence of IRTs, as
isolates containing these enzymes appear to be
resistant at the breakpoint of ‡32 mg ⁄L, while
they are often categorised as susceptible or inter-
mediate when using the ﬁxed 2:1 ratio. A ﬁxed
concentration of clavulanate with amoxycillin is
advocated as the best predictor of likely clinical
efﬁcacy [47]. Another factor to take into account is
that the level of resistance to inhibitor combina-
tions correlates with the amount of IRT enzyme
synthesised, again meaning that low-level pro-
duction could be undetectable when using the
ﬁxed 2:1 ratio [47,48].
As a consequence of these challenges to
detection, the prevalence of IRT enzymes is
probably underestimated. Moreover, and partic-
ularly among E. coli isolates, other resistance
mechanisms, such as the hyperproduction of
parental TEM b-lactamases or the presence of
OXA-type enzymes, may mask or confound a
ﬁrst-glance assessment of an IRT proﬁle.
Although more discernable, the concomitant
presence of porin-mediated loss of permeability,
a low level of chromosomal AmpC production or
a low-level-expressed, plasmid-mediated AmpC
(generally of the CMY type) may make the
detection of an IRT enzyme even more difﬁcult
[48].
EVOLUTION OF IRT ENZYMES AND
IRT-PRODUCING ISOLATES
As previously stated, IRT enzymes have been
mainly described in E. coli isolates and also in
isolates that are naturally resistant to b-lactam–
b-lactamase inhibitor combinations due to
chromosomal AmpC production. In the early
descriptions, IRT enzymes were found in E. coli
and C. freundii isolates from calf faeces [49]. More
recently, TEM-80 (or IRT-24) b-lactamase has been
characterised in an E. cloacae isolate that was
simultaneously recovered with an E. coli isolate
displaying an IRT phenotype from the urine of a
patient living in a nursing home [50]. Similar
conjugative plasmids were characterised in both
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isolates. In addition, TEM-30 (or IRT-2) has been
detected in a K. pneumoniae epidemic strain in
New York, harbouring an acquired carbapenem-
ase (KPC-2) [43]. Phenotypic detection of the
expression of IRT enzymes in these isolates is
difﬁcult, and this enzyme was recognised only
after molecular studies.
From an evolutionary point of view, these
epidemiological ﬁndings raise speculations
about why a given bacterium harbours different
b-lactamase genes that affect the same antimicro-
bials. In a natural AmpC producer, this can be
explained by a mutational event in a previously
acquired blaTEM-1 or blaTEM-2 gene, whereas in a
carbapanemase-producing isolate, it might be a
consequence of the secondary acquisition of a
blaIRT gene. This could also be the case in E. coli or
K. pneumoniae isolates expressing inhibitor-sus-
ceptible b-lactamases such as the TEM-1, TEM-2
or SHV-1 broad-spectrum enzymes [51], in chro-
mosomal OXY-2-producing Klebsiella oxytoca iso-
lates [52] or even in CTX-M-producing
enterobacterial isolates [53].
Different substitutions in the promoter region
of the blaIRT gene coding region can also affect
expression of IRT enzymes, thus affecting poten-
tial selection of IRT-producing isolates. This has
been noted not only in clinical isolates [35] but
also in laboratory-derived mutants [21]. The
introduction of the four promoters known to
control blaTEM gene expression in E. coli isolates
harbouring blaTEM-30 gradually increased IRT
activity and thus amoxycillin–clavulanate MIC
values in relation to the presence of promoters P3,
Pa ⁄Pb and P4 upstream of the corresponding
gene. Promoter P5, only found upstream of the
blaTEM-1B gene, was related to the highest expres-
sion [21].
Complex mutant TEM b-lactamases
One of the most interesting aspects of recent
evolution of IRT enzymes is that, in some cases,
mutations affecting blaTEM may affect the activity
of both b-lactamase inhibitors and the extended-
spectrum cephalosporins. These variants have
been named CMT enzymes (or complex mutant
TEM b-lactamases) and require concurrence of
mutations in the b-lactamase genes of the ESBL
and IRT variants (Table 3). They have been
identiﬁed in different Enterobacteriaceae, includ-
ing E. coli, K. pneumoniae, P. mirabilis and Ente- T
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robacter aerogenes [54–60]. They variably affect
oxyimino-cephalosporin and b-lactamase inhibi-
tor activities. The corresponding phenotype, due
to the expression of CMT b-lactamases in E. coli
in comparison with other b-lactamases, is pre-
sented in Table 1. The expression is not homo-
geneous and can affect different cephalosporins
and penicillin–b-lactamase inhibitor combina-
tions to different extents. Recently, a new
CMT-type b-lactamase, TEM-125, has been char-
acterised in a urinary E. coli isolate; this com-
bines mutations previously described in the
ESBL TEM-12 and in the IRT TEM-39 (IRT-10)
[34,59], conferring high-level resistance to ceftaz-
idime (MICs of 16 mg ⁄L) but not to cefotaxime
(0.06 mg ⁄L), and to penicillin–clavulanate com-
binations (MIC of amoxycillin–clavulanate,
1024 ⁄ 2 mg ⁄L). This phenotype is similar to that
conferred by the last described CMT enzymes,
TEM-151 and TEM-152 [60].
Detection of isolates harbouring CTM enzymes,
because of their clinical implications, could rep-
resent an emerging microbiology problem. The
efﬁciency of ancillary tests based on the synergy
of oxyimino-cephalosporins and clavulanate,
including the double-disk synergy test, can be
reduced in these isolates as a result of high-level
resistance to clavulanate and the variable effect on
cephalosporins.
As with other mutational events, the emergence
of CMT b-lactamase variants might represent a
selection process within a selection compartment
[61]. Most IRT enzymes, as well as CMT enzymes,
have been recovered from urinary isolates, where
amoxycillin–clavulanate and other penicillin–b-
lactamase inhibitor combinations reach high con-
centrations. Potential selection of producers might
also occur in the bowel, where these antibiotics
can produce different selective concentrations
over time and, indeed, some of the new CMT
variants have been characterised in isolates recov-
ered from faeces [55,58,60]. In addition, a higher
prevalence of faecal carriage with amoxycillin–
clavulanate-resistant Gram-negative bacilli,
including E. coli isolates with IRT enzymes, was
demonstrated in patients treated with this com-
bination than in those treated with third-genera-
tion cephalosporins or ﬂuoroquinolones [42].
These faecal isolates can later produce urinary
tract infections or episodes of bacteraemia.
The emergence of mutations conferring both
oxyimino-cephalosporin and clavulanate resis-
tance in CMT variants is also matter for specula-
tion. We can hypothesise that the selection of
ESBL mutations, which do not affect clavulanate,
took place ﬁrst, and then the selection of IRT
mutations; however, the opposite sequence can-
not be excluded. Moreover, although its fre-
quency should be lower, the simultaneous
selection of both variants in the same context
cannot be excluded. An in-vitro model using a
hyper-mutable E. coli strain and a recombinant
plasmid containing the class A b-lactamase ROB-
1 gene was used in selection experiments [62].
Serial passages in tubes containing increasing
concentrations of cefotaxime or amoxycillin–cla-
vulanate revealed the difﬁculty in obtaining
resistance to oxyimino-cephalosporins and cla-
vulanate in the same enzyme. Other research has
shown that there is frequent incompatibility
between both resistance phenotypes, which may
explain the low prevalence of CMT enzymes, as
compared with that of the IRT or ESBL types
[63,64].
Complex mutants of SHV variants with ESBL
mutations and those resembling IRT enzymes
have only very rarely been described, but the
corresponding phenotypes are closely related to
those conferred by the IRT enzymes [65,66]. The
ﬁrst example is the SHV-10 variant, which was
identiﬁed in a urinary E. coli strain resistant to
amoxycillin–clavulanate from a patient previ-
ously treated with this combination. The second
case is the SHV-49 enzyme from a K. pneumoniae
isolate resistant to amoxycillin–clavulanate recov-
ered from a patient treated for over 50 days with
this combination. Both isolates were susceptible to
expanded-spectrum cephalosporins, despite
mutations in both enzymes affecting these
b-lactams.
Inhibitor resistance in CTX-M-producing
isolates
The concomitant presence of IRT enzymes in
producers of CTX-M enzymes has been rarely
described [53]. Moreover, to date, IRT- or CMT-
like enzymes derived from CTX-M types have not
been detected. Rather, the frequent absence of
susceptibility to amoxycillin–clavulanate in iso-
lates harbouring CTX-M enzymes is due to the
simultaneous presence of other b-lactamases,
including OXA-1 and ⁄ or TEM-1, in the same
genetic context. The best example is that of
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CTX-M-15, which is commonly associated with
both OXA-1 and TEM-1, conferring reduced
susceptibility to the amoxycillin–clavulanate
combination [25,67].
THERAPEUTIC OPTIONS IN
INFECTIONS DUE TO PATHOGENS
WITH IRT ENZYMES
As previously stated, the occurrence of IRT
enzymes has been associated with the clinical
failure of b-lactam–b-lactamase inhibitor combi-
nations, particularly in urinary tract infections
[10–12]. Therapeutic options for infections due to
IRT-producing strains are much less limited than
for those due to ESBL or carbapenemase produc-
ers, unless further narrowed by the presence of
other resistance mechanisms affecting b-lactam or
non-b-lactam antibiotics.
In outpatients with non-complicated urinary
tract infections, the use of second-and third-
generation oral cephalosporins, e.g., cefuroxime
or ceﬁxime, would be advised if E. coli—and not
AmpC-inducible species—are involved. If sus-
ceptibility is demonstrated, the alternatives
include ﬂuoroquinolones, fosfomycin, nitrofuran-
toin, co-trimoxazole or even intramuscular ami-
noglycoside, in the case of complicated urinary
infections. For hospitalised patients who require
intravenous therapy, second-generation and ex-
panded-spectrum cephalosporins, aztreonam and
carbapenems, including ertapenem, can be rec-
ommended, as well as ﬂuoroquinolones and
aminoglycosides. As previously stated, piperacil-
lin–tazobactam retains inhibitory activity against
most isolates with IRT enzymes, but no clinical
information regarding its use in this situation has
been published.
CONCLUSION AND FUTURE
DIRECTIONS
IRT enzymes emerged via mutations of broad-
spectrum b-lactamases, mainly from TEM-1. Most
of the information concerning these enzymes
originated during the 1990s, and the number of
subsequent studies updating this knowledge, or
surveys including the prevalence of these en-
zymes, is small. Population structure analysis of
isolates producing these enzymes has not been
undertaken, and the potential clonal spread or
the association of IRT enzymes with speciﬁc
E. coli clonal complexes or virulence traits have
not been studied. Moreover, no information is
available concerning the role of natural or tran-
sient mutators in the evolution of IRT enzymes.
Likewise, studies on the mobilisation of blaIRT
genes and their association with plasmids, similar
to those performed with ESBL and carbapanem-
ase genes, have not been undertaken. From an
epidemiological and clinical point of view, it is
necessary to generate recommendations for better
detection of isolates producing these enzymes
and to enhance our knowledge of risk-factors for
patients.
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